The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 11-18

  Hajek, Roman ^a   Siegel, David ^b   Orlowski, Robert Z ^c   Ludwig, Heinz ^d   Palumbo, Antonio ^e   Dimopoulos, Meletios ^f  

^a UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WILHELMINEN HOSPITAL   (Austria)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bortezomib; Histone deacetylase inhibitor; Immunomodulatory drug; Multiple myeloma; Proteasome inhibitor

Indexed keywords

BELINOSTAT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MELPHALAN; MOCETINOSTAT; PANOBINOSTAT; PREDNISONE; RICOLINOSTAT; ROMIDEPSIN; THALIDOMIDE; TUBACIN; VORINOSTAT;

ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; EVENT FREE SURVIVAL; FATIGUE; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG EVALUATION, PRECLINICAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84891365148     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.797084     Document Type: Review

References (65)

1. Kyle RA, Rajkumar S V. Multiple myeloma. B lood 2 008; 1 11: 2962-2972.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
3. Venner CP, Connors JM, Sutherland HJ, et al. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defi ned by early relapse (-12 months). Leuk Lymphoma 2011; 52: 34-41.
4. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250-5257.
5. Mateos M, Spencer A, Taylor K, et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). J. Clin Oncol 2010; 28(15 Suppl.): Abstract 8030.
6. Siegel DS, Dimopoulos MA, Yoon SS, et al. Vantage 095:vorinostat in combination with bortezomib in salvage multiple myeloma patients: Final study results of a global phase 2b trial. Blood 2011; 118(Suppl. 1): Abstract 480.
7. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431-440.
8. Blade J, Rosinol L. Changing paradigms in the treatment of multiple myeloma. Haematologica 2009; 94: 163-166.
9. Brenner H, Gondos A, Pulte D. R ecent major improvement in long-Term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
10. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867-874.
11. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 2012; 26: 149-157.
12. Vogl DT, Stadtmauer EA, Richardson PG, et al. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J. Haematol 2009; 147: 531-534.
13. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112: 4445-4451.
14. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
15. Yakoub-Agha I, Doyen C, Hulin C, et al. A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: Results of the final analysis of the IFM 01-02 study. J. Clin Oncol 2006; 14(18 Suppl.): Abstract 7520.
16. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma:a randomised trial. Lancet Oncol 2010; 11: 934-941.
17. Jagannath S, Dimopoulos MA, Lonial S. Combined proteasome and histone deacetylase inhibition:A promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 2010; 34: 1111-1118.
18. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell Biochem 2009; 107: 600-608.
19. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-Tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-3449.
20. Hideshima T, Bradner JE, Chauhan D, et al. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res 2005; 11: 8530-8533.
21. Nawrocki ST, Carew JS, Maclean KH, et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008; 112: 2917-2926.
22. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-738.
23. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-5789.
24. Kikuchi J, Wada T, Shimizu R, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010; 116: 406-417.
25. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839-3852.
26. Feng R, Oton A, Mapara MY, et al. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J. Haematol 2007; 139: 385-397.
27. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567-8572.
28. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-2589.
29. Arts J, Angibaud P, Marien A, et al. R 306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J. Cancer 2007; 97: 1344-1353.
30. Golay J, Cuppini L, Leoni F, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007; 21: 1892-1900.
31. Zhang S, Suvannasankha A, Crean CD, et al. The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells. Int J. Cancer 2011; 129: 204-213.
32. Berenson JR, Yellin O, Boccia RV, et al. A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM). Blood 2009; 114(Suppl. 1): Abstract 1855.
33. Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010; 95: 794-803.
34. Campbell RA, Sanchez E, Steinberg J, et al. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J. Haematol 2010; 84: 201-211.
35. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma:biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540-545.
36. Voorhees PM, Gasparetto C, Osman K, et al. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma. Blood 2010; 116(Suppl. 1): Abstract 1955.
37. Ocio EM, San Miguel J. F. Deacetylase inhibitors in multiple myeloma. Presented at 13th International Myeloma Workshop. 3-6 May 2011. Paris, France.
38. Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008; 49: 502-507.
39. Siegel D, Hussein M, Belani C, et al. Vorinostat in solid and hematologic malignancies. J. Hematol Oncol 2009; 2: 31.
40. Wolf JL, Siegel D, Matous J, et al. A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma. Blood 2008; 112(Suppl. 1): Abstract 2774.
41. Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011; 117: 336-342.
42. Gimsing P, Hansen M, Knudsen L M,et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J. Haematol 2008; 81: 170-176.
43. Galli M, Salmoiraghi S, Golay J, et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010; 89: 185-190.
44. Weber D, Badros AZ, Jagannath S, et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: Early clinical experience. Blood 2008; 112(Suppl. 1): Abstract 871.
45. Dimopoulos MA, Jagannath S, Yoon SS, et al. Vantage 088:vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: Results of a global, randomized phase 3 trial. Blood 2011; 118(Suppl. 1): Abstract 811.
46. Richardson P, Weber D, Mitsiades CS, et al. A phase I study of vorinostat, lenalidomide, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma:excellent tolerability and promising activity in a heavily pretreated population. Blood 2010; 116(Suppl. 1): Abstract 1951.
47. Kaufman JL, Shah JJ, Laubach JP, et al. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as frontline therapy for patients with multiple myeloma (MM): Initial results of a phase 1 study. Blood 2010; 116(Suppl. 1): Abstract 3034.
48. Siegel DS, McBride L, Bilotti E, et al. Vorinostat overcomes lenalidomide-dexamethasone and lenalidomide-bortezomibdexamethasone resistance in relapsed/refractory multiple myeloma. Blood 2010; 116(Suppl. 1): Abstract 3065.
49. San Miguel J, Sezer O, Siegel D, et al. A phase Ib dose-escalation study of oral panobinostat (LBH589) and IV bortezomib in patients with relapsed or relapsed and refractory multiple myeloma. Haematologica 2010; 95(Suppl. 2): Abstract 0384.
50. Schlossman RL, Alsina M, Weber DM, et al. PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. Haematologica 2011; 96(Suppl. 2): Abstract 0900.
51. San-Miguel JF, Lonial S, Hungria V, et al. PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. J. Clin Oncol 2011; 29(15 Suppl.): Abstract TPS227.
52. Offidani M, Cavallo F, Polloni C, et al. Melphalan, thalidomide and prednisone (MPT) combined with oral panobinostat in patients with relapsed/refractory MM: A phase I-II study. Blood 2010; 116(Suppl. 1): Abstract 3019.
53. Harrison SJ, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011; 118: 6274-6283.
54. Sullivan D, Singhal S, Schuster M, et al. A phase II study of PXD101 in advanced multiple myeloma. Blood 2006; 108(Suppl. 1): Abstract 3583.
55. Dell ' Aversana C, Lepore I, Altucci L. HDAC modulation and cell death in the clinic. Exp Cell Res 2012; 318: 1229-1244.
56. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003; 2: 721-728.
57. BantscheffM, Hopf C, Savitski MM, et al. Chemoproteomics profi ling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011; 29: 255-265.
58. Hu E, Dul E, Sung CM, et al. Identification of novel isoformselective inhibitors within class I histone deacetylases. J. Pharmacol Exp Ther 2003; 307: 720-728.
59. Fournel M, Bonfi ls C, Hou Y, et al. MGCD0103, anovel isotypeselective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008; 7: 759-768.
60. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916-4921.
61. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-2589.
62. Weber DM, Jagannath S, Mazumder A, et al. Phase I trial of oral vorinostat in combination with bortezomib in advanced multiple myeloma. Haematologica 2008; 93(Suppl. 1): Abstract 0640.
63. Siegel D, Weber DM, Mitsiades CS, et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: A phase I study. J. Clin Oncol 2009; 27(15 Suppl.): Abstract 8586.
64. Offidani M, Polloni C, Cavallo F, et al. Phase II study of melphalan, thalidomide and prednisone (MPT) combined with oral panobinostat in patients with relapsed/refractory MM. Leuk Lymphoma 2012; 53: 1722-1727.
65. Richardson P, Alsina M, Weber D, et al. Phase II study of the pandeacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). Blood 2011; 118(Suppl. 1): Abstract 814.